Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
14
4
2019
medline:
14
4
2019
entrez:
14
4
2019
Statut:
ppublish
Résumé
The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published electronically on the publisher's internet portal (currently SpringerLink) on November 27, 2018 without Open Access.
Identifiants
pubmed: 30980280
doi: 10.1007/s12325-019-00945-2
pii: 10.1007/s12325-019-00945-2
pmc: PMC6824373
doi:
Types de publication
Published Erratum
Langues
eng
Pagination
1200Commentaires et corrections
Type : ErratumFor